Jiangsu Aidea Pharmaceutical Group Co., Ltd. (SHA:688488)
China
· Delayed Price · Currency is CNY 17.30
+0.27 (1.59%)
Apr 29, 2026, 3:00 PM CST
SHA:688488 Revenue
In the year 2025, Jiangsu Aidea Pharmaceutical Group had annual revenue of 719.17M CNY with 72.13% growth. Jiangsu Aidea Pharmaceutical Group had revenue of 166.77M in the quarter ending December 31, 2025, with 40.23% growth.
Revenue
719.17M
Revenue Growth
+72.13%
P/S Ratio
10.12
Revenue / Employee
978.46K
Employees
735
Market Cap
7.28B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 719.17M | 301.37M | 72.13% |
| Dec 31, 2024 | 417.80M | 6.44M | 1.57% |
| Dec 31, 2023 | 411.36M | 167.14M | 68.44% |
| Dec 31, 2022 | 244.22M | -11.49M | -4.49% |
| Dec 31, 2021 | 255.71M | -33.35M | -11.54% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chengdu Kanghua Biological Products | 1.20B |
| Acrobiosystems | 887.21M |
| Nanjing Vazyme Biotech | 1.41B |
| Suzhou Fengbei Biotech Stock | 3.17B |
| Anhui Huaheng Biotechnology | 2.95B |
| Shanghai OPM Biosciences | 354.91M |
| GemPharmatech | 830.61M |
| Daan Gene | 765.48M |